Advances in Research on the Preventive and Therapeutic Effects and Safety of Emodin on Liver Diseases
WANG Hao-ze1,2, LU Hui-ying1, ZHANG Yan-zhe1, PENG Meng-lan1, DA Ming-zhen1, ZHOU Jie1*
1. School of Medicine, Yichun University, Yichun 336000, China; 2. School of Chemical and Biological Engineering, Yichun University, Yichun 336000, China
Abstract：Emodin is an anthraquinone derivative, which is the main active monomer extracted from rhubarb. Modern pharmacological studies have proved that emodin has a wide range of pharmacological activities, including good effects for prevention and treatment of liver diseases such as liver inflammation, liver cancer, liver fibrosis and various types of liver injury, liver failure, fatty liver and so on. However, in the course of research, the potential toxicity of emodin on hepatocytes has also gradually been discovered. Therefore, this article reviews the progress in research on the pharmacological action, mechanism and safety of emodin in the prevention and treatment of liver diseases in recent years in order to provide reference for further, safe and effective application of emodin.
王浩泽, 卢慧颖, 张彦哲, 彭梦兰, 笪明珍, 周婕. 大黄素对肝脏疾病的防治作用与安全性研究进展[J]. 中国药学杂志, 2022, 57(4): 249-257.
WANG Hao-ze, LU Hui-ying, ZHANG Yan-zhe, PENG Meng-lan, DA Ming-zhen, ZHOU Jie. Advances in Research on the Preventive and Therapeutic Effects and Safety of Emodin on Liver Diseases. Chinese Pharmaceutical Journal, 2022, 57(4): 249-257.
LIN W F, WANG C, LING C Q. Research progress in anti-tumor effect of emodin[J]. China J Chin Mater Med (中国中药杂志), 2015, 40(20): 3937-3940.
[2]
LIU F, ZHANG J, QIAN J, et al. Emodin alleviates CCl4-induced liver fibrosis by suppressing epithelial-mesenchymal transition and transforming growth factor-β1 in rats[J]. Mol Med Rep, 2018, 18(3): 3262-3270.
[3]
ZHOU J, LI G, HAN G, et al. Emodin induced necroptosis in the glioma cell line U251 via the TNF-α/RIP1/RIP3 pathway[J]. Investig New Drugs, 2020, 38(1):50-59.
[4]
LIU Y, CHEN X, QIU M, et al. Emodin ameliorates ethanol-induced fatty liver injury in mice[J]. Pharmacology, 2014, 94(1-2):71-77.
[5]
LI W L, WU S P. Clinical efficacy of dahuang zhechong pill on chronic hepatitis with hepatic fibrosis[J]. J China Pharm(中国药房), 2008, 19(21): 1658-1660.
[6]
XU LC, XIA D, FAN H J. Observation on the therapeutic effect of Dahuang Zhezhong Pill on 70 cases of bilirubinemia in viral hepatitis[J]. Heilongjiang Med J (黑龙江医药), 2000, 13(6): 369-370.
[7]
GUO W M, YE J, FU G H, et al. Observation on the therapeutic effect of Dahuang Zhezhong Pill on hepatitis B[J]. Heilongjiang Med J (黑龙江医药), 2000, 13(3): 181.
[8]
LIANG X L. Clinical observation of Dahuang Zhezhong Pill in the treatment of viral hepatitis and cirrhosis[J]. China Foreign Med Treat(中外医疗), 2009, 28(11): 129-130.
[9]
WANG Y M, YU LC. Expert consensus on liver inflammation and its prevention and treatment[J]. Chin J Pract Intern Med (中国实用内科杂志), 2014, 34(2): 152-162.
[10]
WANG Y L, GUO H, WEI M X. Mechanism study of emodin against liver fibrosis induced by CCL4 in mice[J]. Mod Chin Med(中国现代中药), 2018, 20(4): 402-408.
[11]
LIU M Q, ZANG Y, LI J. The roles of hepatic macrophages in tissue homeostasis and liver diseases[J]. Prog Pharm Sci (药学进展), 2018, 42(10): 723-736.
[12]
XUE J H, CHEN F, WANG J, et al. Emodin protects against concanavalin A-induced hepatitis in mice through inhibiting activation of the p38 MAPK-NF-κB signaling pathway[J]. Cell Phys Biochem, 2015, 35(4): 1557-1570.
[13]
WANG X C, JI A G. NF-κB signaling pathway and inflammatory response[J]. Prog Phys Sci(生理科学进展), 2014, 45(1): 68-71.
[14]
XUE J, XIE Q X, CHENG J, et al. Intervention effect of emodin on Con A-induced acute liver injury in mice and its mechanism[J]. Shandong Med J (山东医药), 2019, 59(8): 9-12.
[15]
RAJEEV S, SHAMIM A, ZUZANA B, et al. Agonist anti-GITR antibody significantly enhances the therapeutic efficacy of Listeria monocytogenes-based immunotherapy[J]. J Immunother Cancer, 2017, 5(1):64-72.
[16]
DING Y, LIU P, CHEN Z L, et al. Emodin attenuates lipopolysaccharide-induced acute liver injury via inhibiting the TLR4 signaling pathway in vitro and in vivo[J]. Front Pharmacol, 2018, 9: 962-977.
[17]
DING Y, LIU D Y, LIU P, et al. Therapeutic effects of emodin on acute choiestatic hepatitis and mechanism in rats[J]. Chin J Appl Clin Pediatr(中华实用儿科临床杂志), 2018, 33(19): 1486-1490.
[18]
XU W X, ZHANG Z L, ZHAO S F, et al. Progress on roles and mechanisms of farnesoid X receptor(FXR)in chronic liver diseases[J]. Chin Pharmacol Bull(中国药理学通报), 2016, 32(3): 314-319.
[19]
BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424.
[20]
ELLIS L, KU S Y, RAMAKRISHNAN S, et al. Combinatorial antitumor effect of HDAC and the PI3K-AKT-mTOR pathway inhibition in a Pten defecient model of prostate cancer[J]. Oncotarget, 2013, 4(12): 2225-2236.
[21]
YIN C L, LAO X J. Research progress of PI3K-Akt-mTOR signaling pathway[J]. Med Innov China(中国医学创新), 2016, 13(1): 145-148.
[22]
NI H, WANG Q. The role and mechanism of emodin in inducing apoptosis of human hepatocarcinoma Hep3B cells in vitro[J]. Chin J Gerontol(中国老年学杂志), 2017, 37(14): 3434-3436.
[23]
BAI J G, WU JF, TANG R F, et al. Emodin, a natural anthraquinone, suppresses liver cancer in vitro and in vivo by regulating VEGFR2 and miR-34a[J]. Investig New Drugs, 2020, 38(2): 229-245.
[24]
KIM Y S, LEE Y M, OH T I, et al. Emodin sensitizes hepatocellular carcinoma cells to the anti-cancer effect of sorafenib through suppression of cholesterol metabolism[J]. Int J Mol Sci, 2018, 19(10): 3127-3143.
[25]
BELORIBI-DJEFAFLIA S, VASSEUR S, GUILLAUMOND F. Lipid metabolic reprogramming in cancer cells[J]. Oncogenesis, 2016, 5(1): e189. doi:10.1038/oncsis.2015.49.
[26]
TAKAI H, XIE Y, DE LANGE T, et al. Tel2 structure and function in the Hsp90-dependent maturation of mTOR and ATR complexes[J]. Genes Deve, 2010, 24(18): 2019-2030.
[27]
GAO T, WANG Z X, CHEN Z M. et al. Oxidative stress and autophagy mediated by reactive oxygen species[J]. China Anim Husb Vet Med(中国畜牧兽医), 2018, 45(3): 656-662.
[28]
XING Y X, LI M H, TAO L, et al. Anti-cancer effects of emodin on HepG2 cells as revealed by 1H-NMR based metabolic profiling[J]. J Proteom Res, 2018, 17(5): 1943-1952.
[29]
CHEN J, MEHTA J L, HAIDER N, et al. Role of caspases in Ox-LDL-induced apoptotic cascade in human coronary artery endothelial cells[J]. Circ Res, 2004, 94(3): 370-376.
[30]
XIONG S M, ZHANG J X, KANG W, et al. Emodin induces mitochondrial apoptosis in human hepatoma HepG2 cells[J]. Drug Eval Res(药物评价研究), 2018, 41(5): 773-779.
[31]
LIU D M, ZHOU C Y, WU J S, et al. Emodin induces apoptosis in HepG2 cells via mitochondrial pathway [J]. Chin J Exp Tradit Med Form(中国实验方剂学杂志), 2018, 24(3): 104-108.
[32]
DONG T H, GUO M Z. Roles and mechanisms of RASSF10 in cancers [J]. Chin J Gastroenter Hepatol(胃肠病学和肝病学杂志), 2015, 24(10): 1260-1263.
[33]
LIU X N, LIU X H, YU X X, et al. DNA methylation of tumor suppressor genes and hepatocellular carcinoma[J]. China Cancer(中国肿瘤),2017, 26(9): 727-732.
[34]
YAO M N. The influence of emodin to hepatocellular carcinoma cell HepG2 proliferation and apoptosis and the tumor suppressor RASSF10[D]. Hengyang: Nanhua University, 2017.
[35]
ZHANG Q L, HUAN G J C. Research progress of radiosensitizer of traditional Chinese Medicine[J]. Chin J Clin(中国临床医生杂志), 2014, 42(11): 23-25.
[36]
HWANG S Y, HEO K, KIM J S, et al. Emodin attenuates radioresistance induced by hypoxia in HepG2 cells via the enhancement of PARP1 cleavage and inhibition of JMJD2B[J]. Oncol Rep, 2015, 33(4): 1691-1698.
[37]
AJ KRIEG, EB RANKIN, D CHAN, et al. Regulation of the histone demethylase JMJD1A by hypoxia-inducible factor 1 alpha enhances hypoxic gene expression and tumor growth[J]. Mol Cell Biol, 2010, 30(1):344-353.
[38]
KAWAZU M, SASO K, TONG K I, et al. Histone demethylase JMJD2B functions as a co-factor of estrogen receptor in breast cancer proliferation and mammary gland development[J]. PLoS One, 2011, 6(3): e17830. doi:10.1371/journal.pone.0017830.
[39]
SHI L, SUN L Y, LI Q, et al. Histone demethylase JMJD2B coordinates H3K4/H3K9 methylation and promotes hormonally responsive breast carcinogenesis[J]. PNAS, 2011, 108(18): 7541-7546.
[40]
WANG M F, PING J. The relationship between the main signal transduction pathway of hepatic stellate cells and hepatic fibrosis[J]. J Clin Hepatol(实用肝脏病杂志), 2010, 13(6): 466-469.
[41]
GAO J X, LIU S, REN G P, et al. Effect of emodin on angiogenesis and its mechanism in human hepatoma cell line HepG2[J]. Chin J Cancer Prev Treat(中华肿瘤防治杂志), 2016, 23(3):164-170.
[42]
SUZUKI Y, KITAHARA S, SUEMATSU T, et al. Requisite role of vasohibin-2 in spontaneous gastric cancer formation and accumulation of cancer-associated fibroblasts[J]. Cancer Sci, 2017, 108(12):2342-2351.
[43]
GAO J X, LV Q. Effects of emodin on migration and invasion ability and expressions of E-cadherin and slug of human hepatoma cell lines HepG2[J]. Chin J Inf Tradit Chin Med(中国中医药信息杂志), 2016, 23(6): 64-67.
[44]
WANG G, DENG C L. MAPK pathway and hepatic fibrosis[J]. J Mil Surg Southwest Chin(西南军医), 2010, 12(3): 514-516.
[45]
WANG X L, NIU C G, ZHANG X J, et al. Emodin suppresses activation of hepatic stellate cells through p38 mitogen-activated protein kinase and Smad signaling pathways in vitro[J]. Phytother Res, 2018, 32(12): 2436-2446.
[46]
ZHAO X A, CHEN G M, LIU Y, et al. Emodin alleviates liver fibrosis of mice by reducing infiltration of Gr1hi monocytes[J]. Evid Based Complement Alternat Med, 2018:5738101. http://doi.org/10.1155/2018/5738101.
[47]
TANG Z J, ZHANG M N, CHEN L. Molecular mechanism of EMT and related signal pathways in hepatocellular carcinoma and hepatic fibrosis[J]. Pract J Cancer(实用癌症杂志), 2014, 29(1): 113-116.
[48]
LIVER FAILURE AND ARTIFICIAL LIVER GROUP, SOCIETY OF INFECTIOUS DISEASES, CMA; Severe liver disease and artificial liver group, Chinese society of hepatology, CMA. guideline for diagnosis and treatment of liver failure(2018)[J]. J Pract Hepatol(实用肝脏病杂志), 2019, 22(2): 164-171.
[49]
YU Y, WANG F L. Effects of emodin on liver function in rats with acute liver failure and its mechanism[J]. Zhejiang Med J (浙江医学), 2017, 39(7): 515-517.
[50]
WANG F L. Regulatory effect of emodin on NF-κB signaling pathway in rats with acute liver failure[J]. World Chin J Digestol(世界华人消化杂志), 2018, 26(9): 543-549.
[51]
WANG F L, JIN Q, YU Y, et al. Combined therapy of emodin and bone marrow mesenchymal stem cells transplantation for rat model of acute liver failure[J]. Chin Mod Dr(中国现代医生), 2016, 54(14): 23-26, 30.
[52]
YANG J X, LI Z G, QIU Y, et al. Research progress in differentiation of BMSC into hepatocytes and reconstruction of liver function[J]. Mod Chin Clin Med (北京中医药大学学报 中医临床版), 2009, 16(2): 40-43.
[53]
HA M K, SONG Y H,JEONG S J, et al. Emodin inhibits proin-flammatory responses and inactivates histone deacetylase 1 in hypoxic rheumatoid synoviocytes[J]. Biol Pharm Bull,2011, 34(9): 1432-1437.
[54]
DING Y, ZHAO L, MEI H, et al. Exploration of emodin to treat alpha-naphthyli-sothiocyanate-induced cholestatic hepatitis via anti-inflammatory pathway[J]. Eur J Pharmacol, 2008, 590(1-3): 377-386.
[55]
XU J, BA L, WU W C, et al. Progress in epidemiological study of fatty liver[J]. Chron Pathematol J(慢性病学杂志), 2013, 14(7): 539-542.
[56]
LI J M, DING L L, SONG B L, et al. Emodin improves lipid and glucose metabolism in high fat diet-induced obese mice through regulating SREBP pathway[J]. Eur J Pharmacol, 2016, 770: 99-109.
[57]
KOHJIMA M, ENJOJI M, HIGUCHI N, et al. Re-evaluation of fatty acid metabolism-related gene expression in nonalcoholic fatty liver disease[J]. Int J Mol Med, 2007, 20(3): 351-358.
[58]
WANG S J, LI X J, XU Z M, et al. Improvement of emodin on acute fatty liver in mice[J]. J China Pharm Univ (中国药科大学学报), 2017, 48(1): 89-95.
[59]
KOU X N, XIE X K, HAO M X, et al. Effects of emodin on hepatocyte injury and hepatic inflammation in NASH rats based on SIRT3/FXO1 signaling pathway[J]. Chin Hepatol(肝脏), 2019, 24(5):510-514.
[60]
WANG Y, WANG L, SAXENA R, et al. Clinicopathological features of He Shou Wu-induced liver injury: This ancient anti-aging therapy is not liver-friendly[J]. Liver Int, 2019,39(2):389-400.
[61]
CHANG Y, LIU Q Y, LV C J, et al. Clinical features of 39 patients with acute liver injury induced by polygonum multiflorum[J]. Chin Hepatol(肝脏), 2018, 23(8): 670-672.
[62]
WANG Y Y, SUN X Q, XIA Q, et al. Comprehensive analysis of 40 drug-induced liver injury cases in digestive department ward of a hospital[J]. Anhui Med Pharm J(安徽医药), 2018, 22(3): 579-582.
[63]
JING J, WANG R L, ZHAO X Y, et al. Association between the concurrence of pre-existing chronic liver disease and worse prognosis in patients with an herb- Polygonum multiflorum thunb. induced liver injury: a case-control study from a specialised liver disease center in China[J]. BMJ Open, 2019, 9(1):e023567. doi:10.1136/bmjopen-2018-023567.
[64]
WU X, GUO Y Z I, DU X L, et al. Clinical features of herb-induced liver injury[J]. J Pract Hepatol(实用肝脏病杂志), 2019, 22 (5): 668-671.
[65]
SONG X, ZHANG H Y, CHEN J J, et al. A case of delayed drug hepatitis caused by he Shouwu[J]. Chin Hepatol(肝脏), 2019, 24(9): 1093-1094.
[66]
WANG J, KONG W, WANG H, et al. Toxic effects caused by rhubarb (Rheum palmatum L.)are reversed on immature and aged rats[J]. J Ethnopharmacol, 2011, 134(2): 216-220.
[67]
WANG J, ZHAO H, ZHAO Y, et al. Hepatotoxicity or hepatoprotection? Pattern recognition for the paradoxical effect of the Chinese herb Rheum palmatum L. in treating rat liver injury[J]. PLoS One, 2011, 6(9): e24498. doi:10.1371/journal.pone.0024498.
[68]
WANG Y H, ZHAO H, WANG J B, et al. Study on dosage-toxicity/efficacy relationship of prepared rhubarb on basis of symptom-based prescription theory[J]. China J Chin Mater Med (中国中药杂志), 2014, 39(15): 2918-2923.
[69]
GONG Y S, ZHANG Y N, HUANG W, et al.Research development on chemical compositions of polygonum multiflorum related to efficacy and toxicity[J]. Chin J Pharmacov(中国药物警戒), 2012, 9(8): 472-475.
[70]
HU Y F, XIANG L, WANG P, et al. Hepatotoxicity and nephrotoxicity of rhei radix et rhizoma and its attenuation methods[J]. Chin J Exp Tradit Med Form (中国实验方剂学杂志), 2019, 25(11): 34-41.
[71]
MA Z, ZHAO J R, DONG R R, et al. Hepatotoxicity study of extracts and main components in Polygonum multijiorum using high content analysis[J]. Chin Tradit Herb Drugs(中草药), 2016, 47(22): 4021-4029.
[72]
LIN L F. Study on components and mechanism of liver injury caused by Polygonum multiflorum[D]. Beijing: Beijing University of Traditional Chinese Medicine, 2016.
[73]
HUANG Y J, WANG Q Y, DING J, et al. Determination of emodin in raw and processed products of Polygonum multiflorum[J]. Shaanxi J Tradit Chin Med (陕西中医), 2013, 34(9): 1220-1222.
[74]
ZHAO H X. Analysis of the determination results of emodin in raw and processed products of Polygonum multiflorum[J]. Contemp Med Symp(当代医药论丛), 2014, 12(7): 12-13.
[75]
ZHAO M J, GONG X H, DANG J, et al. Effect of processing time of polygoni multiflori radix on content changes of 16 componens[J]. China J Chin Mater Med (中国中药杂志), 2017, 42(7): 1344-1349.
[76]
YANG L, ZHANG M H, CHEN W M, et al. Study on variation rules of chemical component of Polygonum multiflorum Thunb.during classics and modern method processing[J]. China J Tradit Chin Med Pharm (中华中医药杂志), 2018, 33(2): 770-772.
[77]
HAN L F, WANG P, ZHAO Q Y, et al. Rapid discovery of the potential toxic compounds in polygonum multiflorum by UHPLC/Q-Orbitrap-MS-Based metabolomics and correlation analysis[J]. Front Pharmacol, 2019, 10(329):1-12.
[78]
ZHOU Y J, TANG J F, GAO F, et al. Determination of main chemical constituents in Polygoni multiflori radix after nine steamings and nine sun-dryings and their effect on rat liver[J]. Cent South Pharm(中南药学), 2020, 18(4): 543-548.
[79]
WANG Y L, HU G, ZHANG Q, et al. Effect of processing on the chemical compositions and pharmacological activities of traditional chinese medicines[J]. J Chongqing Univ Technol (Nat Sci)(重庆理工大学学报 自然科学), 2019, 33(5): 127-136.
[80]
WANG J B, MA Y G, ZHANG P, et al. Effect of processing on the chemical contents and hepatic and renal toxicity of rhubarb studied by canonical correlation analysis[J]. Acta Pharm Sin (药学学报), 2009, 44(8): 885-890.
[81]
WANG Q, ZHANG X H, WEN H R, et al. Study on potential hepatotoxicity of main monomers of Polygonummultiflorum based on liver micro-tissue[J]. China J Chin Mater Med (中国中药杂志), 2020, 45(12): 2954-2959.
[82]
SONG J, MA Z J, WANG J B, et al. Study on the effect of he Shouwu and its main components on L02 hepatocyte injury in normal people[J]. Beijing J Tradit Chin Med (北京中医药), 2016, 35(7): 694-697.
[83]
ZHOU X, LUO W J, WANG L P, et al. Study on the toxic mechanism of different components of polygonum multiflorum thunb[J]. J Liaoning Univ Tradit Chin Med(辽宁中医药大学学报), 2019, 21(1): 51-54.
[84]
LIU D M, ZHOU C Y, WU J S, et al. Emodin induces apoptosis of L02 via caspase-8-mediated activation of the mitochondrial death pathway[J]. Pharmacol Clin Chin Mater Med(中药药理与临床), 2017, 33(5): 23-26.
[85]
LIU Y, DONG X X, NI J. Study on the mechanism of emodin-induced apoptosis of hepatocyte L-02[J]. China J Tradit Chin Med Pharm (中华中医药杂志), 2019, 34(5): 2028-2034.
[86]
DONG X X, NI B R, FU J, et al. Emodin induces apoptosis in human hepatocellular carcinoma HepaRG cells via the mitochondrial caspase-dependent pathway[J]. Oncol Rep, 2018, 40(4): 1985-1993.
[87]
WEN H R, MAO Z H, GENG XC, et al. Preliminary validation of high throughput screening methods for hepatotocity and genotoxicity in humanized HepaRG cells[J]. Drug Eval Res(药物评价研究), 2017, 40(11): 1550-1558.
[88]
LIN L, LIU Y, FU S, et al. Inhibition of mitochondrial complex function-the hepatotoxicity mechanism of emodin based on quantitative proteomic analyses[J]. Cells, 2019, 8(3):1-17.
[89]
ZHANG R C, LIU B, SUN Z X, et al. Effects of extract of Polygonum multiflorum on cell cycle arrest and apoptosis of human liver cell line L02[J]. J Integr Med (中西医结合学报), 2010, 8(6): 554-561.
[90]
LEI X, CHEN G, CHEN J. Acute toxicity studies of emodin in mice[J]. Pharmacol Clin Chin Mater Med (中药药理与临床), 2008, (1):32-34.
[91]
National Toxicology Program. Technical report on the toxicology and carcinogenesis studies of emodin in F344/N rats and B6C3F1 mice[J]. Natl Toxicol Prog Tech Rep Ser, 2001, 493: 1-278.
[92]
ZHAO Y L, WANG J B, ZHOU G D, et al. Investigations of free anthraquinones from Rhubarb against αnaphthylisothiocyanate-induced cholestatic liver injury in rats [J]. Basic Clin Pharmacol Toxicol, 2009, 104(6): 463-469.
[93]
DANG S S, ZHANG X, JIA X L, et al. Protective effects of emodin and astragalus polysaccharides on chronic hepatic injury in rats[J]. Chin Med J, 2008, 121(11): 1010-1014.
[94]
DONG M X, JIA Y, ZHANG Y B, et al. Emodin protects rat liver from CCl4-induced fibrogenesis via inhibition of hepatic stellate cells activation[J]. World J Gastroenterol, 2009, 15(38): 4753-4762.
[95]
TU C, GAO D, LI X F, et al. Inflammatory stress potentiates emodin-induced liver injury in rats[J]. Front Pharmacol, 2015, 6(233) doi:10.3389/fphar.2015.00233.
[96]
ZHANG Y H, YANG X W, DAI Y H, et al. Effects of emodin on lipid accumulation and inflammation in hepatocytes[J]. China J Chin Mater Med (中国中药杂志), 2019, 44(13): 2820-2826.
[97]
HOU J, SUN E, SONG J, et al. Relationship between hepatic drug-metabolizing enzymes CYP450 and traditional Chinese medicine-induced hepatotoxicity[J]. China J Chin Mater Med (中国中药杂志), 2016, 41(15): 2774-2780.
[98]
ROBERTSON G, LECLERCQ I, FARRELL G C, et al. Nonalcoholic steatosis and steatohepatitis-Ⅱ. Cytochrome P-450 enzymes and oxidative stress[J]. Am J Physiol Gastrointest Liver Physiol, 2001, 281(5):G1135-G1139.
[99]
FANG X H, YANG D L. Cytochrome P450 and drug-induced liver injury[J]. Chin Hepatol(肝脏), 2001, 6(1): 43.
[100]
HONG M, LI S, TAN H Y, et al. A Network-based pharmacology study of the herb-induced liver injury potential of traditional hepatoprotective chinese herbal medicines[J]. Molecules(Basel, Switzerland), 2017, 22(4):632.
[101]
WANG Q X, LEI R H, WU C Q, et al. Induction of cytochrome P450 enzymes by emodin in liver tissue of rats[J]. Drug Eval Res(药物评价研究), 2015, 38(2): 147-150.
[102]
KANG X L, XUE Y Z, WU R S, et al. Metabolic activities of cytochrome P-450 CYP2E1 and cytochrome P-450 CYP3A in hepatic alcohol-injuried rats[J]. Chin J Pharm Toxicol(中国药理学与毒理学杂志), 2010,24(4): 286-290.
[103]
WANG Z J, LI H, LI D K, et al. Effects of aqueous extract of Polygoni Multiflori Radix and its main constituents on expression of mRNA of CYP1A2, CYP2C9, and CYP2E1 in human liver L02 cells[J]. Chin Tradit Herb Drugs(中草药), 2017, 48(23): 4912-4920.
[104]
WANG Q I, ZHANG Y J, MA S C, et al. Study on the hepatotoxicity of monomers in Polygoni Multiflori Radix on the basis of the inhibition of two-phase metabolic enzymes[J]. Chin J Pharm Anal(药物分析杂志), 2016, 36(12): 2010-2015.
[105]
WEI M J, HUANG J, BAI J Q, et al. Effects of emodin on serum liver function, liver transporter and metabolic enzyme UGT1A1 expression in rats[J]. Lishizhen Med Mater Med Res (时珍国医国药), 2018, 29(7): 1551-1555.
[106]
WU L, HAN W, CHEN Y, et al. Gender differences in the hepatotoxicity and toxicokinetics of emodin: the Potential Mechanisms Mediated by UGT2B7 and MRP2[J]. Mol Pharm, 2018, 15(9): 3931-3945.
[107]
YANG X W, ZHANG Y H, DUAN F P, et al. Study on Mechanism of Liver Injury in Rats Induced by Emodin Based on Lable-free Proteomics Technology[J]. World Chin Med (世界中医药), 2019,14(2): 320-325.
2022, Vol. 57 
